Discuss your full medical history with your clinician before starting treatment
ABSTRACT: The past decade has brought several new developments in the treatment of type 2 diabetes, including the glucagon-like peptide-1 receptor agonists (GLP-1 RAs)
It has been revealing to observe which side of the GLP-1 debate companies are currently coming down on, and more instructive still, will be whether these firms dance to a different tune once the size of the prize begins to manifest itself in coming years
Additionally, the suppression of pro-inflammatory cytokines (e.g., TNF-, IL-6) and inflammatory pathways, including the blocking of NF-B activation [39, 91], contributes to the establishment of an anti-inflammatory environment that can mitigate oxidative stress and inflammation induced muscle protein catabolism, thereby supporting the preservation of SMM and functional capacity [40]
FASEB J 29:38633875
r , Quantification of NMDA-induced (50 M) intracellular calcium rises (%F/F 0 ) following bath application of GLP-1 (1 M, n = 20 neurons) or GLP-1MK-801 (1 M, n = 38 neurons)
